Today Regulus Therapeutics (RGLS) announced that it has received its fourth and final milestone payment from Biogen (BIIB). Regulus earned this milestone payment by using its technology platform in analyzing the effects of a Biogen Multiple Sclerosis — MS — drug on micro RNA profiles. These micro RNA profiles were previously discovered by Regulus when they first identified them. 

The technology platform that Regulus uses to discover targets, especially these MS biomarkers, is known as the microMarkers SM technology. With this technology Regulus can target a wide variety of diseases to go after. Identifying appropriate biomarkers might improve upon the efficacy of current treatments for MS. 

Regulus and Biogen first started this collaboration back in 2012, but it wasn’t until 2014 where both companies came to an agreement for using Regulus’ microMarkers platform to identify appropriate MS biomarkers for clinical development. Under the terms of the agreement Regulus was to receive $3.7 million in payments. The initial agreement has concluded, and there may be the possibility for further collaboration depending upon Biogen’s potential need to advance the program further.